Skip to content

LakeShore Biopharma Co., Ltd

LSBCF LSBWF

CIK 0001946399

← back to feed
Revenue (TTM)
¥85.67M
+6.0% YoY FY Mar 2025
Net Income (TTM)
−¥13.93M
+77.2% YoY FY Mar 2025
EPS Diluted (TTM)
−¥0.73
−28.1% YoY FY Mar 2025
Gross Margin
82.5%
FY Mar 2025
Operating Margin
-14.0%
FY Mar 2025
Net Margin
-16.3%
FY Mar 2025
Free Cash Flow (TTM)
−¥18.62M
FY Mar 2025
Cash
¥53.9M
FY Mar 2025
Total Debt
¥57.67M
FY Mar 2025
Shares Outstanding
20.77M sh
FY Mar 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings